GNA Axles Promoter Group Member Sells 5 Lakh Shares
Maninder Singh Seehra, a member of the promoter group of GNA Axles, disposed of 5,00,000 equity shares through an inter-se transfer.
GNA Axles Promoter Shareholding Change
Maninder Singh Seehra, part of the promoter group of GNA Axles, disposed of 5,00,000 equity shares through an inter-se transfer.
Before the transaction, Seehra held 15,82,106 shares, representing 3.69% of the company's total voting capital. After the transfer, his holding stood at 10,82,106 shares, representing 2.52%.
GNA Axles Share Transfer Details
The disclosure states that the transaction was an inter-se transfer. The shares were transferred on September 11, 2026, while the disclosure was intimated to the stock exchanges on September 14, 2026.
The filing was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
GNA Axles Share Capital After Promoter Transfer
The company's total equity share capital remained unchanged at 42,93,08,000 shares before and after the transaction.
Following the transfer, Maninder Singh Seehra continued to hold 10,82,106 shares, equivalent to 2.52% of the total voting capital.
GNA Axles Promoter Stake Sale Highlights
- Promoter Group Member: Maninder Singh Seehra
- Shares Disposed: 5,00,000 equity shares
- Holding Before Transfer: 15,82,106 shares, or 3.69%
- Holding After Transfer: 10,82,106 shares, or 2.52%
- Transaction: Inter-se transfer
- Date of Transfer: September 11, 2026
- Disclosure Date: September 14, 2026
- Total Equity Share Capital: 42,93,08,000 shares
- Regulatory Disclosure: Regulation 29(2) of the SEBI (SAST) Regulations, 2011
What to Watch Next
- Investors may track further changes in the promoter group's shareholding in GNA Axles.
- They can monitor any additional disclosures relating to share transfers, acquisitions or disposals by promoter group members.
- Investors may also review subsequent shareholding disclosures to assess changes in the promoter group's overall holding.
Disclaimer: The information provided is for informational purposes only and should not be considered investment advice or a recommendation to buy or sell securities.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.